Atricure Inc Dossier - Source-backed chat

Atricure Inc

ATRCNASDAQ

SectorHealth Care

IndustryMedical Instruments & Supplies

Beta (adjusted)1.16

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $56.20Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $2.9B

Enterprise Value $2.8B

Shares Outstanding 49.3M diluted

Moat Rating None

Next Earnings Date27 Oct 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

AtriCure is transitioning from a niche medical device player into a highly profitable, standard-of-care leader in surgical atrial fibrillation (Afib) treatment, left atrial appendage (LAA) management, and post-operative pain management. The company's growth is driven by rapid adoption of high-margin products like the AtriClip FLEX-Mini and cryoSPHERE MAX probe, which pushed Q1 2026 gross margins to 77.4%. Crucially, AtriCure is executing on two landmark clinical trials (LeAAPS and BoxX-NoAF) that are running ahead of schedule. The BoxX-NoAF trial is on track to complete enrollment by the end of 2026, potentially unlocking a massive new prophylactic market in 2027. With a clear path to positive GAAP net income in FY 2026 and a long-term target of $1 billion in revenue by 2030, AtriCure represents a compelling growth story with expanding operating leverage.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets9 analysts · as of 18 Aug 2026

Low · most bearish analyst$36.00

Mean target$47.33

High · most bullish analyst$55.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$36.0010%

Increased competition in the LAA management space (e.g., from catheter-based technologies or new surgical entrants) erodes AtriCure's market share. Clinical trial costs or R&D spending escalate, delaying GAAP net income sustainability. BoxX-NoAF data shows weaker-than-expected efficacy in preventing post-operative Afib, limiting TAM expansion.

Base CaseCentral scenario

$47.3360%

Matches the consensus mean

AtriCure achieves its FY 2026 guidance of $600M to $610M in revenue (12% to 14% growth) and $80M to $82M in Adjusted EBITDA, reaching full-year GAAP net profitability. BoxX-NoAF completes enrollment by year-end 2026, and LeAAPS continues its steady follow-up. Steady market share retention of >90% in surgical LAA exclusion supports a valuation multiple expansion toward historical averages.

Bull CaseUpside scenario

$55.0030%

The BoxX-NoAF trial delivers outstanding results in 2027, establishing concomitant ablation and LAA exclusion as the standard of care for all cardiac surgery patients, expanding the addressable market significantly. European commercialization of FLEX-Mini and PRO-Mini accelerates international growth above 20%, while U.S. pain management adoption continues at a >25% clip. Operating leverage drives EBITDA margins past 20% ahead of the 2030 target.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Dominant market position with over 90% market share in surgical left atrial appendage exclusion.
Strong financial profile characterized by high gross margins (77.4% in Q1 2026) and accelerating operating leverage.
Accelerated clinical trial timelines, with the BoxX-NoAF trial running 12 months ahead of schedule.
Clear long-term strategic vision targeting $1 billion in revenue and >20% Adjusted EBITDA margins by 2030.

Key Investment Risks

Intense competition from catheter-based electrophysiology procedures and alternative surgical devices.
Heavy reliance on specialized cardiothoracic surgeons, making adoption sensitive to training and clinical guidelines.
Near-term profitability pressure from elevated R&D and clinical trial execution expenses.

Thesis Invalidation Triggers

A failure of the BoxX-NoAF trial to show a statistically significant reduction in post-operative atrial fibrillation.
A structural decline in gross margins below 72% due to pricing pressure or unfavorable product mix.
Regulatory delays or safety concerns raised during the ongoing LeAAPS trial follow-up.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.